TY - JOUR
T1 - Effects of systemic anti-androgen drugs on the ocular surface
AU - Aydin Kurna, S.
AU - Oflaz Hacisalihoglu, A.
AU - Altun, A.
AU - Ozbay Ozel, N.
AU - Uruc, F.
AU - Kanar, H. S.
AU - Karatay Arsan, A.
N1 - Publisher Copyright:
© 2021 Elsevier Masson SAS
PY - 2022/6
Y1 - 2022/6
N2 - Purpose: To investigate the effect of systemic anti-androgen drugs on tear function tests and the ocular surface. Methods: Sixty-four male subjects were included in this study. Subjects who were on anti-androgen treatment for prostate cancer (Group A, n: 31) and those who had received only surgical treatment for prostate cancer (Group B, n: 17) were recruited from the department of urology. Age-matched subjects who had never received anti-androgen treatment (Group C, n: 16) constituted the control group. Group A was divided into two subgroups according to the number of anti-androgen drugs used (Group A1: one drug, Group A2: two drugs). All cases underwent a complete ocular examination, including tear film break up time (TBUT), corneal and conjunctival staining, Schirmer 1 test, conjunctival impression cytology, and ocular surface disease index (OSDI) questionnaire. Results: The mean Schirmer's values were 6.87 mm, 11.41 mm, and 13.03 mm in Groups A, B, and C, respectively (P = 0.001). TBUT was 5.45 ± 2.01, 9.85 ± 2.52 and 9.81 ± 1.96 seconds in Groups A, B, and C, respectively (P = 0.001). Schirmer and TBUT were significantly lower, and corneal staining and OSDI questionnaire scores were higher in Group A compared to groups B and C (P < 0.01). Conjunctival impression cytology results according to the Nelson grading system revealed no statistically significant difference between the groups (P = 0.422). Conclusion: Anti-androgen drugs alter tear function tests, cause increased corneal and conjunctival staining scores and worsen complaints of dry eye in patients with prostate cancer.
AB - Purpose: To investigate the effect of systemic anti-androgen drugs on tear function tests and the ocular surface. Methods: Sixty-four male subjects were included in this study. Subjects who were on anti-androgen treatment for prostate cancer (Group A, n: 31) and those who had received only surgical treatment for prostate cancer (Group B, n: 17) were recruited from the department of urology. Age-matched subjects who had never received anti-androgen treatment (Group C, n: 16) constituted the control group. Group A was divided into two subgroups according to the number of anti-androgen drugs used (Group A1: one drug, Group A2: two drugs). All cases underwent a complete ocular examination, including tear film break up time (TBUT), corneal and conjunctival staining, Schirmer 1 test, conjunctival impression cytology, and ocular surface disease index (OSDI) questionnaire. Results: The mean Schirmer's values were 6.87 mm, 11.41 mm, and 13.03 mm in Groups A, B, and C, respectively (P = 0.001). TBUT was 5.45 ± 2.01, 9.85 ± 2.52 and 9.81 ± 1.96 seconds in Groups A, B, and C, respectively (P = 0.001). Schirmer and TBUT were significantly lower, and corneal staining and OSDI questionnaire scores were higher in Group A compared to groups B and C (P < 0.01). Conjunctival impression cytology results according to the Nelson grading system revealed no statistically significant difference between the groups (P = 0.422). Conclusion: Anti-androgen drugs alter tear function tests, cause increased corneal and conjunctival staining scores and worsen complaints of dry eye in patients with prostate cancer.
KW - Anti-androgen
KW - Dry eye
KW - Ocular surface
KW - Prostate cancer
UR - http://www.scopus.com/inward/record.url?scp=85129116311&partnerID=8YFLogxK
U2 - 10.1016/j.jfo.2021.06.007
DO - 10.1016/j.jfo.2021.06.007
M3 - Article
C2 - 35489988
AN - SCOPUS:85129116311
SN - 0181-5512
VL - 45
SP - 619
EP - 627
JO - Journal Francais d'Ophtalmologie
JF - Journal Francais d'Ophtalmologie
IS - 6
ER -
